In Arthritis Consumer Experts’ (ACE) April JointHealth™ insight, we explore what “personalized and precision medicine” – the theme to this year’s Canadian Rheumatology Association Annual Meeting and Arthritis Health Professions Association Annual Meeting – means to arthritis patients and health care providers. To help you, we have prepared a curated guide to a selection of #CRArthritis interviews, outlining key points covered during the event.
Among the topics of interest to patients, the interviews provide information on:
- Personalized and precision medicine
- Juvenile arthritis
- Spondyloarthritis and psoriatic arthritis – Advancements in diagnosis and therapy
- Giant cell arteritis and vasculitis
- Exercise as medicine
- Medication adherence
- Medical marijuana and pain management
- Improving access to and quality of arthritis care
- New research on preventing rheumatoid arthritis
- Communicating with your doctor
- Teamwork and patient-centred care in arthritis Models of Care
All interviews can be accessed through YouTube, Twitter, and Facebook.
To turn on French subtitles, please adjust the YouTube settings for each interview.
BC PharmaCare is looking for your input on tocilizumab (Actemra™) for the treatment of giant cell arteritis
Tocilizumab (Actemra®) for giant cell arteritis (GCA) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tocilizumab for the treatment of GCA.
You can give input if you are a B.C. resident and have giant cell arteritis, a caregiver to someone with giant cell arteritis, or if your group represents people who live with giant cell arteritis.
If you would like our help in providing your input, you can email us your input at firstname.lastname@example.org or call us at 604-974-1366. We can send it as a patient organization on your behalf. Please provide your input to us by Monday, February 19 so that we may submit the questionnaire in time for the deadline.
The submission deadline is midnight on February 21, 2018. Patients and caregivers may give their input directly through the links below.
Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:
- To view the information sheet for tocilizumab for giant cell arteritis: click here
- For the Patient Questionnaire: click here
- For the Caregiver Questionnaire: click here
- For the Patient Group Questionnaire: click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)
Call for patient input on tocilizumab (Actemra®) for giant cell arteritis
Do you have giant cell arteritis? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of giant cell arteritis.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.
These are the questions they are asking: Continue reading